Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees him succeed Flemming Pederson at the pharmaceutical company.
Jelert most recently served as a general manager for NNE, an engineering company that specialises in supporting pharmaceutical company engineering projects.
He said: “This new role offers me the opportunity to use my knowledge and experience to support and further develop ALK as it works to build a new growth platform and to become a truly global allergy company.”
His career has seen him serve in various capacities for Novo Nordisk, including as finance director Europe North and manager operations, finance.
Carsten Hellmann, president and chief executive officer, ALK, said: “Søren brings a wealth of experience to ALK, in particular from his previous pharmaceutical industry-focused roles at NNE and Novo Nordisk.
“He has a proven track record of financial leadership and he has also played a pivotal role in transformation processes that are comparable to the one we are embarking upon at ALK.”
Jelert will be based at ALK’s headquarters in Hørsholm, Denmark and will report directly to Hellmann.